Consuming ten portions of tomatoes a week can lower the risk of prostate cancer.
Significant association observed for high-risk prostate cancers with no difference according to daily dose.
Vitamin D may be able to suppress inflammation in prostate tissue by boosting expression of the GDF-15 gene.
Fathering of dizygotic twins, a marker of high fertility, was not associated with increased risk of prostate cancer.
New data confirms that ConfirmMDx, an epigenetic assay, is able to accurately identify prostate cancer aggressiveness
Testosterone replacement therapy (TRT) may promote prostate cancer tumor growth.
Findings suggest that normalization of blood fats may reduce risk of prostate cancer.
Mortality was greater with external beam radiotherapy across treatment-specific nomograms for predicting biochemical recurrence.
Researchers confident in this approach because candidates for active surveillance are a heavily screened population.
A biomarker present on the KLK3 gene can predict which GS7 prostate cancer patients will be more aggressive.
Growth in robot-assisted radical prostatectomy (RARP) use especially pronounced among surgeons at urban hospitals.
Meta-analysis shows that the risk is increased 20% with each 20 cigarettes smoked per day.
Urologic complications requiring hospital admission grew from 3.6% in 2000 to 3.9% in 2008, largely because of infections.
Outcomes of robot-assisted radical prostatectomy in obese patients are mostly comparable to non-obese patients.
Men who had PSA relapse after receiving post-radical surgery salvage radiation therapy had a median overall survival of nearly 14 years.
Radiotherapy given within 6 months of radical prostatectomy reduces cancer-specific mortality in men with highly aggressive disease.
Prostate cancer patients undergoing radical prostatectomy increased by double digits while those undergoing brachytherapy decreased.
High rates of preserved sexual function with combination beam plus brachytherapy.
Utilization rates jumped by double digits across prostate cancer risk groups from 2004 to 2011.
Men with male pattern baldness may face a higher risk of aggressive prostate cancer.
This benefit is not seen in patients who undergo radical prostatectomy, according to an updated meta-analysis.
Black prostate cancer patients more likely to develop aggressive disease earlier than white patients.
Low-dose aspirin decreased the likelihood of acute genitourinary toxicity in prostate cancer by 27%.
Enzalutamide and abiraterone may not benefit men with metastatic castration-resistant prostate cancer who have AR-V7 in circulating tumor cells.
However, they are more likely to die from causes other than prostate cancer than men with normal metabolic levels.
The drug is now also approved for use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer.
Study finds a 15-year cancer-specific survival rate of 94%; hormone therapy for more than 6 months decreases all-cause survival.
Detection of AR-V7 in circulating tumor cells linked to enzalutamide and abiraterone resistance.
New study highlights the importance of digital rectal examinations in PCa patients with normal-range PSA at diagnosis.
Findings seen in economically disadvantaged men with newly diagnosed prostate cancer.